GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » Scaled Net Operating Assets

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Scaled Net Operating Assets : 0.71 (As of Sep. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sucampo Pharmaceuticals's operating assets for the quarter that ended in Sep. 2017 was $313.1 Mil. Sucampo Pharmaceuticals's operating liabilities for the quarter that ended in Sep. 2017 was $55.0 Mil. Sucampo Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2017 was $365.1 Mil. Therefore, Sucampo Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2017 was 0.71.


Sucampo Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Sucampo Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sucampo Pharmaceuticals Scaled Net Operating Assets Chart

Sucampo Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.40 0.10 1.63 0.57

Sucampo Pharmaceuticals Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.56 0.43 0.44 0.71

Competitive Comparison of Sucampo Pharmaceuticals's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sucampo Pharmaceuticals's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sucampo Pharmaceuticals's Scaled Net Operating Assets falls into.



Sucampo Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sucampo Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2016 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2016 )
=(Operating Assets (A: Dec. 2016 )-Operating Liabilities (A: Dec. 2016 ))/Total Assets (A: Dec. 2015 )
=(322.543-63.236)/457.181
=0.57

where

Operating Assets(A: Dec. 2016 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=520.851 - 198.308
=322.543

Operating Liabilities(A: Dec. 2016 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=353.752 - 290.516 - 0
=63.236

Sucampo Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2017 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2017 )
=(Operating Assets (Q: Sep. 2017 )-Operating Liabilities (Q: Sep. 2017 ))/Total Assets (Q: Jun. 2017 )
=(313.103-54.971)/365.083
=0.71

where

Operating Assets(Q: Sep. 2017 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=388.144 - 75.041
=313.103

Operating Liabilities(Q: Sep. 2017 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=348.51 - 293.539 - 0
=54.971

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sucampo Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.
Executives
Peter Greenleaf officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell director
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan officer: Sr. Vice Pres., BD & Licensing C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener officer: Chief Science Officer 40 GUEST STREET, BOSTON MA 02135
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp other: Former Officer 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin director 18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris officer: Chief Acctg. Officer, Treas. C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Headlines